Menu Search
Equities

Arrowhead Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HDP1:STU

Arrowhead Pharmaceuticals Inc

Actions
  • Price (EUR)16.16
  • Today's Change0.46 / 2.93%
  • Shares traded0.00
  • 1 Year change-36.43%
  • Beta0.9567
Data delayed at least 15 minutes, as of Jul 18 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener
Looking for Financials, specific market tools, news or data?
Director dealings, financials and forecasts are now only available to FT.com subscribers. To access these valuable tools and see the full perspective, subscribe now.
Subscribe
Already a subscriber?
Access exclusive markets data when you subscribe to the FT
Our extensive director dealings data, financial analysis, and forecasts are now only available to FT.com subscribers. To benefit from this content, plus our exclusive data archive, subscribe to the FT today. Subscribers benefit from access to:
Director Dealings
Take a deeper look into a company's insider transactions by viewing director purchases and sales by individual directors.

5-year financials
The interactive charting tool provides extensive upper and lower indicators, news and fundamental overlays, and comparison features.

Sectors and Industries Content
Track sectors and industries performance, see top performing companies, and find news relevant to you.

A Comprehensive Research Platform
Access bonds data, league tables and trends, world markets, macro maps and data archives.

Most Read

An average of 120 articles are published each week. Here are the most read:
  1. Donald Trump calls for release of Jeffrey Epstein testimony
  2. University of California fund ditches hedge funds with scathing rebuke
  3. Rising graduate joblessness is mainly affecting men. Will that last?
See stories that matter, from every angle. Subscribe to the FT now
Subscribe

Most Read

An average of 120 articles are published each week. Here are the most read:
  1. Donald Trump calls for release of Jeffrey Epstein testimony
  2. University of California fund ditches hedge funds with scathing rebuke
  3. Rising graduate joblessness is mainly affecting men. Will that last?
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.